Keywords

• (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid
• Amitiza
• 7-[(1R,4R,6R,9R)-4-(1,1-Difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo[4.3.0]non-9-yl]heptanoic acid

Quick Details

• ProName: Lubiprostone
• CasNo: 136790-76-6
• Molecular Formula: C20H32F2O5
• ProductionCapacity: /
• Purity: 99
• LimitNum: 0

Superiority

Details

Lubiprostone, marketed under the brand name Amitiza, is a medication used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. It is also indicated for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Lubiprostone is a locally acting chloride channel activator that works by increasing intestinal chloride and fluid secretion, which in turn stimulates bowel movements.

The drug is a bicyclic fatty acid derived from a metabolite of prostaglandin E1 (PGE1) and is classified as a prostone. It specifically activates ClC-2 chloride channels, leading to an efflux of chloride ions into the intestinal lumen and subsequent water secretion. This results in increased gastrointestinal motility and softer stools, alleviating constipation symptoms.

Lubiprostone is available in oral capsule form, with dosages of 24 mcg twice daily for chronic idiopathic constipation and opioid-induced constipation, and 8 mcg twice daily for IBS-C in women. The capsules should be taken with food and water, and the drug is generally well-tolerated. Common side effects may include nausea, diarrhea, and abdominal pain. More serious side effects are less frequent but can include severe diarrhea, which may require discontinuation of the drug.